JPRN-UMIN000031004招募中2 期
Phase 2 study of gemcitabine and docetaxel chemotherapy for advanced bone and soft tissue sarcomas - GD therapy for advanced sarcomas
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 10years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Active double cancers within 5 years(cured intraepithelial carcinoma and intramucosal carcinoma are not included) 2)Cases with complications of severe infection 3)Body temperature more than 38 degree 4)Pregnant or breastfeeding women 5)Severe psychological disease 6) 7)Unstable angina (within 3 months after onset) , myocardial infarction 8)Difficult-to-control hypertension 9)Difficult-to-control diabetes 10)HBs antigen is positive 11)Judgment to attending physician
研究者
相似试验
招募中
2 期
GD therapy for advanced sarcomasadvanced pretreated bone and soft tissue sarcomasJPRN-jRCTs051180042Hara Hitomi20
进行中（未招募）
不适用
Phase II study with gemcitabine/docetaxel first line in women with metastatic breast cancer - SF- 2Gem/taxoncological patients onlyMedDRA version: 6.1Level: PTClassification code 10055113EUCTR2005-006168-71-ITA.S.L. 270
进行中（未招募）
1 期
A fase I/II trial with docetaxel and gemcitabine in hormone refractory prostate cancerHormone fractory prostate cancerEUCTR2004-002353-31-DKOrganisation name was not entered60
招募中
2 期
Study of gemcitabine docetaxel in synovial sarcoma in relapsed metastatic settingCTRI/2020/02/023612Department of Medical Oncology
进行中（未招募）
不适用
Phase II study with gemcitabine/docetaxel fist line in women with metastatic breast cancer. - SF2gem/taxOncologic patients only.MedDRA version: 6.1Level: PTClassification code 10055113EUCTR2006-000165-10-ITA.S.L. 2 SAVONA70